We are live on
!
Find out more
ACP
Acuta Capital Partners Portfolio holdings
AUM
$142M
1-Year Est. Return
783.79%
This Fund
S&P 500
This Quarter
Est. Return
+21.43%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$277M
AUM Growth
-$90.1M
(-25%)
Cap. Flow
-$75.2M
Cap. Flow
% of AUM
-27.11%
Top 10 Holdings %
Top 10 Hldgs %
45.56%
Holding
64
New
13
Increased
10
Reduced
20
Closed
18
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
VistaGen Therapeutics
VTGN
|
+$10.7M |
| 2 |
VINC
Vincerx Pharma, Inc. Common Stock
VINC
|
+$7.95M |
| 3 |
EPIX
ESSA Pharma
EPIX
|
+$6.67M |
| 4 |
CMRX
Chimerix, Inc.
CMRX
|
+$6.5M |
| 5 |
Aclaris Therapeutics
ACRS
|
+$6.21M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Larimar Therapeutics
LRMR
|
+$18.5M |
| 2 |
Celldex Therapeutics
CLDX
|
+$14M |
| 3 |
Immunovant
IMVT
|
+$13.1M |
| 4 |
SAGE
Sage Therapeutics
SAGE
|
+$11.3M |
| 5 |
CMPS
Compass Pathways
CMPS
|
+$10M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 91.38% |
| 2 | Financials | 5.21% |
| 3 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
VistaGen Therapeutics
VTGN
$10.1M
| $26.2M | 9.44% |
409,859
+159,859
| +64% | +$10.7M |
|
|
2
Celldex Therapeutics
CLDX
$2.96B
| $21M | 7.56% |
1,017,524
-609,976
| -37% | -$14M |
|
3
Kura Oncology
KURA
$816M
| $15.2M | 5.47% |
536,820
-100,680
| -16% | -$3.19M |
|
|
AVDL
4
DELISTED
Avadel Pharmaceuticals
AVDL
| $9.9M | 3.57% |
1,095,000
+389,782
| +55% | +$3.15M |
|
|
ISEE
5
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $9.76M | 3.52% |
1,579,093
+366,593
| +30% | +$2.23M |
|
|
ETNB
6
DELISTED
89bio
ETNB
| $9.32M | 3.36% |
393,548
-40,852
| -9% | -$943K |
|
|
BLSA
7
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
| $8.91M | 3.21% |
843,122
+622
| +0.1% | +$7.02K |
|
|
SAGE
8
DELISTED
Sage Therapeutics
SAGE
| $8.87M | 3.2% |
118,500
-137,300
| -54% | -$11.3M |
|
9
Curis
CRIS
$10M
| $8.69M | 3.13% |
1,919
+594
| +45% | +$2.48M |
|
|
SEEL
10
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
| $8.58M | 3.09% |
+448
| New | +$5.23M |
|
|
EPIX
11
DELISTED
ESSA Pharma
EPIX
| $8.34M | 3.01% |
+287,000
| New | +$6.67M |
|
|
12
Aclaris Therapeutics
ACRS
$772M
| $8.01M | 2.89% |
+317,730
| New | +$6.21M |
|
|
VINC
13
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
| $7.6M | 2.74% |
+19,700
| New | +$7.95M |
|
14
Xenon Pharmaceuticals
XENE
$6.02B
| $7.38M | 2.66% |
412,500
+332,500
| +416% | +$5.64M |
|
|
LONA
15
LeonaBio Inc
LONA
$70.2M
| $7.36M | 2.65% |
40,000
+700
| +2% | +$154K |
|
16
Fulcrum Therapeutics
FULC
$283M
| $7.33M | 2.64% |
622,500
-60,000
| -9% | -$742K |
|
17
Arrowhead Research
ARWR
$12.1B
| $7.16M | 2.58% |
108,000
-31,000
| -22% | -$2.41M |
|
|
TRIL
18
DELISTED
Trillium Therapeutics Inc.
TRIL
| $7.11M | 2.56% |
661,565
-141,435
| -18% | -$1.75M |
|
|
CMRX
19
DELISTED
Chimerix, Inc.
CMRX
| $6.82M | 2.46% |
+707,830
| New | +$6.5M |
|
|
MRSN
20
DELISTED
Mersana Therapeutics
MRSN
| $5.79M | 2.09% |
14,308
-13,452
| -48% | -$6.52M |
|
21
Altimmune
ALT
$583M
| $5.75M | 2.07% |
407,055
-171,445
| -30% | -$2.77M |
|
22
Syndax Pharmaceuticals
SNDX
$1.7B
| $5.71M | 2.06% |
255,180
-210,320
| -45% | -$4.75M |
|
23
Verastem
VSTM
$500M
| $5.67M | 2.04% |
191,116
-8,884
| -4% | -$249K |
|
|
JYAC
24
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
| $5.54M | 2% |
562,500
| – | – |
|
25
Praxis Precision Medicines
PRAX
$8.52B
| $5.05M | 1.82% |
10,282
+5,239
| +104% | +$3.73M |
|
Similar funds
EC
YEPX
SR
IA
MAM
HA
VVM
KCAM
Acuta Capital Partners's Q1 2021 Portfolio in Review
As of Q1 2021, Acuta Capital Partners held 64 positions worth $277M, down 25% from $367M the previous quarter. Its ten largest holdings account for 46% of the portfolio.
Acuta Capital Partners withdrew a net $75.2M in Q1 2021, closing 18 positions and reducing 20 holdings. Its most notable exit was Larimar Therapeutics, an estimated $18.5M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 89% a quarter earlier, followed by Financials and Industrials.
Against the trend, Acuta Capital Partners opened a new position in Vincerx Pharma, Inc. Common Stock worth $7.6M.
- Acuta Capital Partners's largest Q1 2021 buy was Vincerx Pharma, Inc. Common Stock: 19,700 shares worth $7.6M.
- Acuta Capital Partners added most to VistaGen Therapeutics in Q1 2021, an estimated $10.7M increase.
- Acuta Capital Partners's biggest Q1 2021 reduction was Celldex Therapeutics, cutting an estimated $14M.
- Acuta Capital Partners fully exited Larimar Therapeutics in Q1 2021, selling an estimated $18.5M.
- Acuta Capital Partners's ten largest holdings make up 46% of its $277M portfolio in Q1 2021.
- Acuta Capital Partners opened 13 new positions and closed 18 in Q1 2021.
- Acuta Capital Partners's portfolio value fell 25% quarter-over-quarter to $277M.
Based on Acuta Capital Partners's 13F filing for Q1 2021, filed 17 May 2021.